WuXi Biologics (Cayman) (WXXWY) Stock Price, News & Analysis

Company Overview

WuXi Biologics (Cayman) is a global contract research, development and manufacturing organization (CRDMO) focused on biologic medicines. The company provides integrated services to pharmaceutical and biotechnology customers across the development cycle, from early-stage discovery and preclinical research through clinical development, regulatory support and commercial manufacturing.

Its capabilities include the development and production of monoclonal antibodies, recombinant proteins, vaccines, antibody-drug conjugates and other biologic modalities. WuXi Biologics offers cell-line development, process development, clinical-trial material manufacturing, analytical testing and large-scale commercial production, with services designed to help customers advance biologic candidates from laboratory research to marketed products.

Founded in 2010 and headquartered in China, WuXi Biologics has expanded its operations internationally through facilities and offices serving customers in Asia, North America and Europe. The company is led by Chief Executive Officer Dr. Chris Chen and operates as part of the broader WuXi platform of pharmaceutical research and manufacturing services.

Key Stats

• Today's Range: $12.61 to $13.34
• 50-Day Range: $9.47 to $13.05
• 52-Week Range: $7.30 to $13.43
• Volume: 26,085 shs
• Average Volume: 70,528 shs
• Market Capitalization: $26.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

WuXi Biologics (Cayman) Stock Analysis - MarketRank™

WuXi Biologics (Cayman) scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

WuXi Biologics (Cayman) has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

WuXi Biologics (Cayman) has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 19.57%

Earnings Growth

Earnings for WuXi Biologics (Cayman) are expected to grow by 19.57% in the coming year, from $0.46 to $0.55 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of WuXi Biologics (Cayman) has been sold short.

Short Interest Ratio / Days to Cover

WuXi Biologics (Cayman) has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in WuXi Biologics (Cayman) has recently decreased by 9.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WuXi Biologics (Cayman) does not currently pay a dividend.

Dividend Growth

WuXi Biologics (Cayman) does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

WuXi Biologics (Cayman) has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for WuXi Biologics (Cayman) this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, WuXi Biologics (Cayman) insiders have not sold or bought any company stock.

Percentage Held by Institutions

WuXi Biologics (Cayman) has minimal institutional ownership at this time.

Company Calendar

• Today: 9/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:WXXWY
• CIK: N/A
• Web: www.wuxibiologics.com.cn
• Phone: 8651081831205
• Fax: N/A
• Employees: 12,435
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,074,860,000
• Free Float: N/A
• Market Cap: $26.54 billion
• Optionable: Not Optionable
• Beta: N/A